Acute Repetitive Seizures Market – By Product, By Route of Administration, By Distribution Channel Industry & Forecast, 2024 – 2032

Acute Repetitive Seizures Market Size

The global acute repetitive seizures market in 2023 was valued at USD 2.7 billion and is poised to grow at 12.4% CAGR over the forecast period. The market is growing significantly due to the increasing prevalence of epilepsy and advancements in rescue therapies.
 

According to the World Health Organization, approximately 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. Similarly, the Centers for Disease Control and Prevention (CDC) reports that about 3.4 million people in the U.S., including 470,000 children, have active epilepsy, highlighting the substantial potential market for these therapies.
 

Furthermore, the development of intranasal formulations, such as USL-261 (intranasal midazolam) and NRL-1 (intranasal diazepam), has significantly impacted the market. These newer therapies provide fast, non-invasive administration, enhancing accessibility for patients and caregivers, particularly in home settings. The convenience and simplicity of intranasal therapies are driving their adoption, as they enable quick intervention without requiring medical supervision, thereby contributing to market growth.
 

Acute repetitive seizures (ARS), also known as seizure clusters or flurries, refer to a series of seizures that occur within a short time frame, usually between 24 and 48 hours, with the risk of escalating into status epilepticus—a life-threatening condition. ARS is common among epilepsy patients, particularly those who struggle to maintain full control over their seizures, making it a critical focus for treatment solutions. Management of ARS typically involves rescue medications, such as benzodiazepine drugs (e.g., diazepam, midazolam), administered to halt seizure activity and prevent escalation. Treatment aims to reduce seizure frequency, prevent further clusters, and protect against complications.
 

Acute Repetitive Seizures Market Trends

• The rising prevalence of epilepsy and seizure disorders is a key driver of the ARS market.
   
• According to the National Institute of Neurological Disorders and Stroke (NINDS), epilepsy affects people of all ages, with onset most common in children and older adults. Approximately 1 in 26 people will develop epilepsy at some point in their lifetime. The Epilepsy Foundation reports that about 30-40% of people with epilepsy continue to have seizures despite treatment. Among these, many experience seizure clusters or acute repetitive seizures.
   
• The growing number of epilepsy patients directly increases the demand for treatments to manage associated complications, including seizure clusters (SC) or acute repetitive seizures (ARS), which are common among people with epilepsy (PWE).
   
• As more epilepsy patients report experiencing seizure clusters, the demand for effective ARS treatments is rising, contributing to market growth.
   
• Furthermore, the high prevalence of epilepsy has encouraged pharmaceutical companies to invest in developing user-friendly, fast-acting treatments. These include intranasal rescue medications and other therapies that offer non-invasive administration, driving market expansion.
   

Acute Repetitive Seizures Market Analysis

Based on product, the market is classified into USL-261, diastat rectal gel (DRG), NRL-1, and other products. The USL-261 segment held market share of 35.2% in 2023.
 

• The high growth of this segment can be attributed to the convenience and non-invasiveness of the USL-261 solution. Additionally, its intranasal delivery system enables rapid absorption, providing swift seizure control, which is crucial in emergency situations.
   
• Another factor contributing to the significant market share of USL-261 is its FDA approval for the treatment of seizure clusters in patients with epilepsy, bolstering its credibility and adoption.
   
• Moreover, the rising preference for home-based seizure management has increased the demand for easy-to-use rescue therapies, further driving the adoption of USL-261.
   

Based on route of administration, the acute repetitive seizures market is segmented into intranasal, rectal, oral, and other routes of administration. The intranasal segment was valued at USD 1.2 billion in 2023.
 

• The growth of the intranasal route of administration is driven by its non-invasive, convenient, and rapid drug delivery method, which is essential for effectively managing seizure emergencies.
   
• Rapid absorption through the nasal mucosa ensures immediate action, helping to prevent the escalation of seizure clusters into life-threatening conditions like status epilepticus.
   
• Furthermore, the rising demand for homecare settings has significantly increased the adoption of intranasal therapies such as USL-261 and NRL-1, which are easy to use and do not require medical supervision.
   

Based on distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to grow at a CAGR of 12.2% during the analysis timeframe.
 

• The rising incidence of acute repetitive seizures often leads to hospital admissions, creating a higher demand for effective seizure management medications within hospital pharmacies.
   
• Additionally, these pharmacies frequently collaborate with neurologists and emergency care teams to develop protocols for managing seizures, enhancing the effectiveness and availability of treatments for patients.
   
• Owing to these factors, the hospital pharmacies segment is poised to witness continuous growth in the coming years.
   

North America acute repetitive seizures market was valued at USD 1.1 billion in 2023 and is expected to grow lucratively at 12.3% CAGR.
 

• The high prevalence of epilepsy in the region drives demand for effective treatments, while a robust healthcare infrastructure facilitates timely diagnosis and management.
   
• For instance, the National Association of Epilepsy Centers (NAEC) reports that there are over 260 specialized epilepsy centers in the U.S.
   
• Additionally, increased awareness and education about seizure disorders have led to more frequent diagnoses, further boosting market demand.
   
• Moreover, the introduction of innovative treatment options, including fast-acting and non-invasive medications, enhances patient care, supported by frequent regulatory approvals for new therapies.
   
• These factors collectively contribute to the market's substantial growth potential.
   

In 2023, the U.S. market was valued at USD 1 billion and is projected to reach USD 2.8 billion by 2032.
 

• The Centers for Disease Control and Prevention reports that approximately 2.9 million U.S. adults aged 18 and older have active epilepsy, representing about 1% of the adult population.
   
• This high prevalence of epilepsy indicates a significant number of individuals potentially experiencing acute repetitive seizures (ARS), driving the demand for effective treatment options and contributing to the market's growth potential.
   

China acute repetitive seizures market is predicted to showcase remarkable growth over the forecast period.
 

• The increasing prevalence of epilepsy, combined with growing government healthcare investments, is improving access to diagnosis and treatment for seizure disorders. According to the World Health Organization, the prevalence of epilepsy in China is estimated to be 7 per 1,000 population, affecting approximately 9 million people.
   
• Additionally, the expansion of specialized neurological clinics and hospitals is improving access to ARS treatments. Collectively, these factors create a strong foundation for significant growth in the ARS market in China.
   

India is expected to witness significant growth in Asia Pacific market.
 

• With an estimated prevalence of around 1 to 2 percent of the population affected by epilepsy, the rising incidence of neurological disorders is driving demand for effective ARS treatments.
   
• The Indian government's initiatives, such as Ayushman Bharat, aim to enhance healthcare access and affordability, facilitating necessary treatments for patients. Additionally, increased investment in research and development within the pharmaceutical sector is fostering innovation in therapies for ARS.
   
• These aforementioned factors are expected to support market growth in the country.
   

Acute Repetitive Seizures Market Share

The acute repetitive seizures industry is increasingly dynamic, driven by both established pharmaceutical companies and emerging biopharmaceutical firms. This competitive edge is further enhanced by ongoing research and development efforts aimed at introducing novel therapies that address unmet medical needs. The market is also witnessing collaborations and partnerships between companies and healthcare providers to enhance the delivery and effectiveness of seizure management solutions.
 

Acute Repetitive Seizures Market Companies

Prominent players operating in the acute repetitive seizures industry include:

• AdvaCare Pharma Limited
• Aquestive Therapeutics
• Bausch Health Companies
• Lupin Limited
• Neuracle Lifesciences
• Neurelis
• Pfizer
• Sanofi
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries
• UCB S.A.
• Veriton Pharma
   

Acute Repetitive Seizure Industry News:

• In April 2024, the FDA approved Libervant buccal film by Aquestive Therapeutics for treating intermittent, stereotypic episodes of frequent seizure activity, including seizure clusters and acute repetitive seizures, in patients aged 2 to 5 years. This approval helped the company to expand its product offerings in the pediatric market, potentially increasing revenue and enhancing its reputation in innovative seizure management therapies.
   

The acute repetitive seizures market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• USL-261
• Diastat rectal gel (DRG)
• NRL-1
• Other products

Market, By Route of Administration

• Intranasal
• Rectal
• Oral
• Other routes of administration

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE